Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
International ‘dream team’ to use new technologies and prevention approaches to help those at highest risk.
Results of a two-year study of a monoclonal antibody combined with induction chemotherapy to treat children with the disease were positive.
“It was amazing to see the tumors shrink over time; and if this helps other people in the future, that’s even better.”
Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease.
The three studies tested Zejula, Lynparza and veliparib in women with newly diagnosed advanced ovarian cancer.
In a clinical trial, the research team is hoping to learn more about how myeloma cells resist CAR T-cell therapy.
“The more information we have from well-designed studies, the better we are able to counsel our patients,” said Larissa Korde, MD.
The findings hold particular promise for people who haven’t been helped by the targeted drug tagraxofusp.
This type of ovarian cancer is the deadliest form of the disease largely because it doesn’t respond to chemotherapy.
The #NWMetsConf connects metastatic breast cancer patients with trials, treatments, tools and each other.
Engineered immune cells get a helping hand in a new clinical trial for multiple myeloma patients.
Recent legislation may help narrow the gap between FDA approval of cancer medications for adults and children.
Scientists emphasize using data and analyses from completed and ongoing trials to gain a better understanding of patient outcomes.
Forty-five percent of 182 phase 3 clinical trials between 1980 and 2017 influenced guideline care or new drug approvals.
Surprising new research suggests why 97% of cancer drugs in clinical trials fail to stop cancer in patients and never make it to market.
Gaby Kressly, now in her early 80s, was diagnosed with ovarian cancer in 2016.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.